Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
Patient Preference and Adherence · 2024-01 · Volume 18 · 69-88
DOI: 10.2147/ppa.s437396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Patient Preference and Adherence, 2024-01. Verfasst von Oralee J Varnado und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, IN, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, IN, USA.
- Merative, Ann Arbor, MI, USA.
Zitieren
APA
Varnado, O. J., Brady, B. L., Zagar, A. J., Robles, Y. P., & Hoyt, M. (2024). Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study. Patient Preference and Adherence, Volume 18, 69-88. https://doi.org/10.2147/ppa.s437396
Vancouver
Varnado OJ, Brady BL, Zagar AJ, Robles YP, Hoyt M. Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study. Patient Preference and Adherence. 2024;Volume 18:69-88. doi:10.2147/ppa.s437396
BibTeX
@article{Varnado2024,
author = {Varnado, Oralee J and Brady, Brenna L and Zagar, Anthony J and Robles, Yvonne P and Hoyt, Margaret},
title = {Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study},
journal = {Patient Preference and Adherence},
year = {2024},
volume = {Volume 18},
pages = {69--88},
doi = {10.2147/ppa.s437396}
}
EUVIMED